The first U.K. patient has been treated with an experimental drug for severe lung disease related to Covid-19, the Manchester University NHS Foundation Trust said Monday. The patient is part of the Oscar study conducted by U.K. pharmaceutical giant GlaxoSmithKline PLC, set up to investigate whether one of its pipeline drugs, Otilimab, can help reduce the effects of the so-called cytokine storm--a severe immune reaction where the body starts to attack its own cells--which was found to occur in some hospitalized Covid-19 patients.

Source: Wall Street Journal September 27, 2020 23:15 UTC